Halitosis Treatment Through the Administration of Antibiotic-Resistant Probiotic Lactic Yeast Kluyveromyces marxianus fragilis B0399 (K-B0399)

Cecchini F*¹, Nobili A², Zanvit A³, Miclavez A⁴ and Nobili P^3,5

Received: November 23, 2018;   Published: December 11, 2018

DOI: 10.26717/BJSTR.2018.12.002180

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Halitosis (oral malodour) is a common problem, which creates severe social and relational difficulties. The most popular approach is to mask the smell, without considering the bacterial aetiology of the problem. The aim of this study is to demonstrate the efficacy of the administration of encapsulated Kluyveromyces marxianus B0399 by measuring the amount of VSC (Volatile Sulphur Compounds) with follow-up at 7 and 14 days. At the end of treatment, about 91% of patients did not present halitosis. The protocol did not consider any oral hygiene treatment. The drug is in capsule form with a shell. Therefore, results were achieved with a direct action on the intestine, not at an oral level. In conclusion, this study proves that, besides the rebalancing effect of probiotics in dysbiosis, there are many immunological implications on GALT (Gut Associated Lymphoid Tissue).

Keywords :Halitosis; Kluyveromyces Marxianus B0399; Probiotic; Probiotic Lactic Yeast; Biosympa®

Abbreviations : VSC: Volatile Sulphur Compounds; GALT: Gut Associated Lymphoid Tissue; WHO: World Health Organization; SCFAs: Short-Chain Fatty Acids